FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

_					
$\circ$	MR	AΡ	PR	O١	/ΔΙ

OMB Number:	3235-0287
Estimated average burde	n
hours per response:	0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Hame and Haaroos of Hoperang Forcen			2. Issuer Name <b>and</b> Ticker or Trading Symbol  RESMED INC [ RMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
I		` ,	3. Date of Earliest Transaction (Month/Day/Year) 12/15/2021	X	Officer (give title below)  President and C	Other (specify below)		
9001 SPECTRUM CENTER BLVD.  (Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applica     X Form filed by One Reporting Person     Form filed by More than One Reporting				
SAN DIEGO	CA	92123			•	, , , , , , , , , , , , , , , , , , ,		
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
ResMed Common Stock	12/15/2021		<b>M</b> <sup>(1)</sup>		8,000	A	\$58.24	25,175	D	
ResMed Common Stock	12/15/2021		S <sup>(1)</sup>		8,000	D	\$256.52	17,175	D	
ResMed Common Stock								234,995	I	Douglas Family Trust

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Deriva Secur Acqui or Dis	ities red (A) posed (Instr. 3,	6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	Reported	vative Unities Form: Direct (D) or Indirect owing (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
ResMed Common Stock Options	\$58.24	12/15/2021		M			8,000	11/11/2016 <sup>(2)</sup>	11/19/2022	ResMed Common Stock	8,000	\$0	86,098	D	

## Explanation of Responses:

- 1. The transaction was conducted under a Rule 10b5-1 plan.
- 2. Represents date options first became exercisable. Options vest 1/3 per year.

Robert Douglas, President and Chief Operating Officer, ResMed 12/16/2021 Inc.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.